PDF(Pubmed)
Abstract：
Marker research, and in particular urine bladder cancer marker research throughout the past three decades, devours enormous scientific resources in terms of manpower (not to mention time spent on reviewing and editorial efforts) and financial resources, finally generating large numbers of manuscripts without affecting clinical decision making. This is mirrored by the fact that current guidelines do not recommend marker use due to missing level 1 evidence. Although we recognize the problems and obstacles, the authors of this commentary feel that the time has come to abandon the current procedures and move on to prospective trial designs implementing marker results into clinical decision making. Our thoughts and concerns are summarized in this comment.
摘要：
标记研究,特别是在过去的三十年中，尿液膀胱癌标志物的研究，在人力(更不用说花在审查和编辑工作上的时间)和财政资源方面吞噬了巨大的科学资源，最终产生大量的手稿，而不影响临床决策。由于缺少1级证据，因此当前指南不建议使用标记物，这反映了这一点。尽管我们认识到问题和障碍，本评论的作者认为,现在是时候放弃目前的程序,转而进行前瞻性试验设计,将标志物结果纳入临床决策.本评论总结了我们的思绪和存眷。
